We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Serum Extracellular Vesicle Arginase 1 Measured In T2DM

By LabMedica International staff writers
Posted on 18 Mar 2022

Type 2 diabetes mellitus (T2DM) has become one of the most pressing and prevalent epidemics in the last few decades and is associated with an increased risk of cardiovascular and cerebrovascular diseases with high mortality and disability. More...

Emerging evidence suggests that specific molecules derived from body fluids such as urine and blood are also closely associated with the presence of diabetes or diabetes-related diseases. As a new type of biomarker resource, extracellular vesicles (EVs) presented in accessible biofluids have garnered considerable attention due to their high stability in body fluids.

Medical Scientists at the Beijing Anzhen Hospital (Beijing, China) and their colleagues performed a cross-sectional study in 103 Chinese between the age of 32 and 89, including 73 T2DM patients and 30 non-T2DM. An overnight fasting blood sample was drawn from each participant into a serum collection tube. Serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and other serum biochemical indexes were measured by biochemical analyzer (Hitachi 7600, Tokyo, Japan).

After centrifugation processing, the number and size of EVs was measured by Nanoparticle Tracking Analysis with a Nanosight NS300 instrument (Malvern, UK). Serum Extracellular Vesicle Arginase 1 (EV-derived ARG 1) concentration was measured using Human Arginase 1 Simplestep ELISA Kit (Abcam, Inc., Burlingame, CA, USA), a highly sensitive enzyme-linked immunosorbent assay kit. The OD value at 450 nm was recorded by an EnSpire microplate reader (Perkin Elmer Singapore Pte. Ltd., Singapore). Chemiluminescence signals from Western Blotting were visualized using supersensitive chemiluminescent substrates (Thermo Fisher Scientific, Waltham, MA, USA) and detected by an imaging system (Bio-Rad, Hercules, CA, USA).

The investigators reported that serum EV-derived ARG 1 levels were significantly higher in T2DM patients compared with non-T2DM patients. Correlation analysis revealed that serum EV-derived ARG 1 levels were positively associated with fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c). Serum EV-derived ARG 1 levels were significantly associated with T2DM, especially in the subgroup of T2DM for more than 10 years (Odds Ratio (OR) = 1.651), after adjusting for confounding factors.

The authors concluded that their study there was a significant association between serum EV-derived ARG 1 levels and the presence and duration of T2DM. It would help explain in part that more vascular diseases occur in T2DM compared to non-T2DM. The study was published on March 11, 2022 in the journal BMC Endocrine Disorders.

Related Links:
Beijing Anzhen Hospital 
Hitachi 
Nanosight 
Abcam 
Perkin Elmer Singapore 
Thermo Fisher Scientific
Bio-Rad 

 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
Biochemistry Analyzer
Chemi+ 8100
New
Whole Blood Control
Lyphochek Whole Blood Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.